An Efficacy and Safety Study of SRM003 in the Treatment of Subjects Undergoing Placement of an Arteriovenous Graft to Facilitate Hemodialysis Access

NCT ID: NCT01806584

Last Updated: 2021-06-08

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE2

Total Enrollment

32 participants

Study Classification

INTERVENTIONAL

Study Start Date

2013-03-28

Study Completion Date

2014-10-23

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A study to evaluate the efficacy of SRM003 treatment versus participating sites' standard practice treatment in extending the duration of primary patency after arteriovenous graft surgery in subjects with end-stage renal disease.

It is hypothesized that when placed outside the blood vessel, the seeded SRM003 gelatin matrix containing endothelial cells can provide a continuous supply of multiple growth regulatory compounds to the underlying cells within the blood vessel, while being protected from the effects of blood flow in the vessel(s) or complications resulting from being in direct contact with the point of injury.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Arteriovenous Graft

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

SRM003

Group Type ACTIVE_COMPARATOR

SRM003

Intervention Type BIOLOGICAL

One time implant (3 SRM003 pieces) on surgery day.

Participating Site's standard practice

Group Type OTHER

Participating Site's standard practice

Intervention Type OTHER

Subjects will receive sites' standard practice treatment during the surgical procedure

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

SRM003

One time implant (3 SRM003 pieces) on surgery day.

Intervention Type BIOLOGICAL

Participating Site's standard practice

Subjects will receive sites' standard practice treatment during the surgical procedure

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Allogeneic human aortic endothelial cells cultured in a gelatin matrix (Gelfoam®).

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Subject must be 18 years of age or older at the time of signing and dating informed consent (no upper age limit), can be male or female.
2. Subject who is of child bearing potential must agree to use adequate contraception for 6 months after randomization.
3. Subject must be currently undergoing hemodialysis or anticipating the start of hemodialysis and must require a new permanent prosthetic expanded polytetrafluoroethylene AVG placed in the upper extremity.
4. Subject must have a life expectancy of at least 78 weeks after randomization.
5. Subject must be able to understand and be willing to complete all study requirements.

Exclusion Criteria

1. Subject is currently on an active organ transplant list from a deceased donor or is undergoing assessment and expects to be placed on the active organ or bone marrow transplant list within the next 78 weeks from surgery, or expects to receive a living donor organ or bone marrow within the next 78 weeks and is unwilling to change transplant list status to "hold" for 3 months after randomization.
2. Subject has had more than 3 access placement surgeries (defined as a new access, not a revision) in the target limb.
3. Subject has medical conditions and diseases that may cause non-compliance with the protocol
4. Subject has a known allergy to bovine/porcine products or collagen/gelatin products.
5. Subject has a history of intravenous drug use within 6 months prior to screening
6. Subject is morbidly obese, defined as having a body mass index \>40.
7. Pregnant or nursing woman, or plans to become pregnant during the study.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Shire

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Study Director

Role: STUDY_DIRECTOR

Takeda

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Akdhc Medical Research Services

Phoenix, Arizona, United States

Site Status

Tucson Vascular Consultants

Tucson, Arizona, United States

Site Status

Ladenheim Dialysis Access Center

Fresno, California, United States

Site Status

California Institute of Renal Research

La Mesa, California, United States

Site Status

VA Long Beach Health Care System Pharmacy

Long Beach, California, United States

Site Status

The Regents University of California Los Angeles

Los Angeles, California, United States

Site Status

California Institute of Renal Research

San Diego, California, United States

Site Status

University of California, San Francisco

San Francisco, California, United States

Site Status

University of Colorado Denver

Aurora, Colorado, United States

Site Status

Yale University School of Medicine

New Haven, Connecticut, United States

Site Status

Tampa General Hospital

Tampa, Florida, United States

Site Status

Georgia Regents University

Augusta, Georgia, United States

Site Status

Illinois Kidney Disease & Hypertension Center

Peoria, Illinois, United States

Site Status

University of Louisville

Louisville, Kentucky, United States

Site Status

Ochsner Baptist Medical Center, Clinical Trials Unit

New Orleans, Louisiana, United States

Site Status

Louisiana State University Health Science Center Shreveport

Shreveport, Louisiana, United States

Site Status

Baystate Medical Center Pharmacy

Springfield, Massachusetts, United States

Site Status

Henry Ford Hospital

Detroit, Michigan, United States

Site Status

Renaissance Renal Research Institute, LLC

Detroit, Michigan, United States

Site Status

McLaren Northern Michigan Hospital-NISUS Research

Petoskey, Michigan, United States

Site Status

Providence Hospital, Research Dept.

Southfield, Michigan, United States

Site Status

Clinical Research Consultants, LLC

Kansas City, Missouri, United States

Site Status

Washington University School of Medicine

St Louis, Missouri, United States

Site Status

Sierra Nevada Nephrology Consultants

Reno, Nevada, United States

Site Status

United Health Services

Johnson City, New York, United States

Site Status

Mount Sinai School of Medicine Lab

New York, New York, United States

Site Status

Montefiore Medical Center

The Bronx, New York, United States

Site Status

Metrolina Nephrology Associates, PA

Charlotte, North Carolina, United States

Site Status

ECU Department of Nephrology and Hypertension

Greenville, North Carolina, United States

Site Status

Sanford Research/USD-Fargo

Fargo, North Dakota, United States

Site Status

University of Cincinnati Physicians Company

Cincinnati, Ohio, United States

Site Status

The Cleveland Clinic Foundation

Cleveland, Ohio, United States

Site Status

The Ohio State University

Columbus, Ohio, United States

Site Status

Toledo Hospital

Toledo, Ohio, United States

Site Status

Kaiser Permanente Northwest

Milwaukie, Oregon, United States

Site Status

Northwest Renal Clinic, Inc.

Portland, Oregon, United States

Site Status

Penn Medicine, Perelman Center for Advanced Medicine

Philadelphia, Pennsylvania, United States

Site Status

Delaware Valley Nephrology and Hypertension Associates, PC

Philadelphia, Pennsylvania, United States

Site Status

Temple University School of Medicine

Philadelphia, Pennsylvania, United States

Site Status

SC Nephrology & Hypertension Center, Inc.

Orangeburg, South Carolina, United States

Site Status

Erlanger Hospital Pharmacy

Chattanooga, Tennessee, United States

Site Status

Nephrology Associates, P.C.

Nashville, Tennessee, United States

Site Status

Baylor College of Medicine ICTR

Houston, Texas, United States

Site Status

Fletcher Allen Health Care Renal Service

Burlington, Vermont, United States

Site Status

Sentara Vascular Specialists

Norfolk, Virginia, United States

Site Status

University of Wisconsin

Madison, Wisconsin, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

AVG01-SRM003

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Use of a Lifeline Graft in the A-V Shunt Model
NCT00850252 COMPLETED PHASE1/PHASE2
Barrow Ruptured Aneurysm Trial
NCT01593267 UNKNOWN NA